Experience and pharmacokinetics of Levetiracetam in Korean neonates with neonatal seizures / 소아과
Korean Journal of Pediatrics
;
: 50-54, 2017.
Article
in English
| WPRIM
| ID: wpr-168713
ABSTRACT
PURPOSE:
The aims of this study were to evaluate the safety and pharmacokinetics of levetiracetam (LEV) in neonates with seizures and to establish a population pharmacokinetics (PPK) model by using the software NONMEM.METHODS:
A retrospective analysis of 18 neonatal patients with seizures, who were treated with LEV, including 151 serum samples, was performed. The mean loading dose was 20 mg/kg, followed by a mean maintenance dose of 29 mg/kg/day.RESULTS:
Seventeen neonates (94%) had seizure cessation within 1 week and 16 (84%) remained seizure-free at 30 days under the LEV therapy. The mean serum concentration of LEV was 8.7 µg/mL. Eight samples (5%) were found above the therapeutic range. No serious adverse effects were detected. In the PPK analysis for Korean neonates, the half-life was 9.6 hours; clearance, 0.357 L/hr; and volume of distribution, 4.947 L, showing differences from those in adults.CONCLUSION:
LEV is a safe and effective option for the treatment of neonatal seizures with careful therapeutic drug monitoring.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Seizures
/
Pharmacokinetics
/
Retrospective Studies
/
Drug Monitoring
/
Half-Life
Type of study:
Observational study
Limits:
Adult
/
Humans
/
Infant, Newborn
Language:
English
Journal:
Korean Journal of Pediatrics
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS